Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials - PubMed
4 hours ago
- #HIV-1
- #B/F/TAF
- #Renal Impairment
- Integrated analysis of 9 phase 3/3b clinical trials involving 1069 people with HIV-1 and mild to moderate renal impairment.
- Participants were treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) over up to 240 weeks.
- Renal function remained generally stable throughout the follow-up period.
- Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.